| 2001 |
Borah B, Gross GJ, Dufresne TE, Smith TS, Cockman MD, Chmielewski PA, Lundy MW, Hartke JR, Sod EW. Three‐dimensional microimaging (MRμI and μCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. Anat Rec. April 15, 2001;265(2):101-110. |
32 |
31 |
| 2006 |
Bingham CO III, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier J-P, Raynauld J-P, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. November 2006;54(11):3494-3507. |
21 |
21 |
| 1995 |
Boyce RW, Wronski TJ, Ebert DC, Stevens ML, Paddock CL, Youngs TA, Gundersen HJG. Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. Bone. February 1995;16(2):209-213. |
11 |
10 |
| 1995 |
Boyce RW, Ebert DC, Youngs TA, Paddock CL, Mosekilde L, Stevens ML, Gundersen HJG. Unbiased estimation of vertebral trabecular connectivity in calcium-restricted ovariectomized minipigs. Bone. June 1995;16(6):637-642. |
15 |
14 |
| 1995 |
Forwood MR, Burr DB, Takano Y, Eastman DF, Smith PN, Schwardt JD. Risedronate treatment does not increase microdamage in the canine femoral neck. Bone. June 1995;16(6):643-650. |
19 |
9 |
| 1995 |
Sietsema WK. Animal models of cortical porosity. Bone. October 1995;17(4):S297-S305. |
16 |
16 |
| 1995 |
Mackey MS, Stevens ML, Ebert DC, Tressler DL, Combs KS, Lowry CK, Smith PN, McOsker JE. The ferret as a small animal model with BMU-based remodelling for skeletal research. Bone. October 1995;17(4)(suppl):S191-S196. |
6 |
6 |
| 2001 |
van Staa TP, Dennison EM, Leufkens HGM, Cooper C. Epidemiology of fractures in England and Wales. Bone. January 2001;29(6):517-522. |
54 |
45 |
| 2002 |
Eriksen E, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. November 2002;31(5):620-625. |
27 |
23 |
| 2004 |
Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. April 2004;34(4):736-746. |
34 |
33 |
| 2005 |
Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J, Phipps RJ, Turner RT. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone. July 2005;37(1):1-9. |
23 |
22 |
| 2006 |
Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. October 2006;39(4):872-879. |
49 |
34 |
| 2020 |
Watts NB, Chesnut CH III, Genant HK, Harris ST, Jackson RD, Licata AA, Miller PD, Mysiw WJ, Richmond B, Valent D. History of etidronate. Bone. May 2020;134:115222. |
3 |
3 |
| 2003 |
Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tiss Int. November 2003;73(5):423-432. |
21 |
19 |
| 1999 |
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD; Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. October 13, 1999;282(14):1344-1352. |
103 |
86 |
| 2001 |
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA. January 17, 2001;285(6):320-323. |
62 |
55 |
| 1999 |
Cody DD, Gross GJ, Hou FJ, Spencer HJ, Goldstein SA, Fyhrie DP. Femoral strength is better predicted by finite element models than QCT and DXA. J Biomech. October 1999;32(10):1013-1020. |
111 |
106 |
| 2000 |
Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. June 2000;15(6):993-1000. |
24 |
18 |
| 2000 |
Borah B, Dufresne TE, Cockman MD, Gross GJ, Sod EW, Myers WR, Combs KS, Higgins RE, Pierce SA, Stevens ML. Evaluation of changes in trabecular bone architecture and mechanical properties of minipig vertebrae by three‐dimensional magnetic resonance microimaging and finite element modeling. J Bone Miner Res. September 2000;15(9):1786-1797. |
17 |
13 |
| 2002 |
Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three‐dimensional microcomputed tomography. J Bone Miner Res. July 2002;17(7):1139-1147. |
24 |
21 |
| 2003 |
Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. June 2003;18(6):1051-1056. |
28 |
23 |
| 2005 |
Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, Cahall DL; IMPACT Study Group. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res. April 2005;20(4):557-563. |
22 |
21 |
| 2005 |
Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. December 2005;20(12):2097-2104. |
18 |
17 |
| 2006 |
Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res. July 2006;21(7):1106-1112. |
17 |
15 |
| 2006 |
Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K. Bone material properties in trabecular bone from human iliac crest biopsies after 3‐ and 5‐year treatment with risedronate. J Bone Miner Res. October 2006;21(10):1581-1590. |
22 |
16 |
| 2007 |
Burge R, Dawson‐Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis‐related fractures in the United States, 2005–2025. J Bone Miner Res. March 2007;22(3):465-475. |
183 |
183 |
| 2008 |
Fuchs RK, Allen MR, Ruppel ME, Diab T, Phipps RJ, Miller LM, Burr DB. In situ examination of the time-course for secondary mineralization of Haversian bone using synchrotron Fourier transform infrared microspectroscopy. Matrix Biol. January 2008;27(1):34-41. |
17 |
15 |
| 2000 |
Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R; Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. January 2000;11(1):83-91. |
70 |
59 |
| 2001 |
Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int. August 2001;12(7):519-528. |
21 |
16 |
| 2002 |
van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. October 2002;13(10):777-787. |
21 |
19 |
| 2008 |
Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. June 2008;19(6):733-759. |
58 |
54 |
| 2009 |
Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int. July 2009;20(6):887-894. |
51 |
30 |
| 1998 |
Dufresne T. Segmentation techniques for analysis of bone by three-dimensional computed tomographic imaging. Technol Health Care. 1998;6(5-6):351-359. |
22 |
17 |